Rockefeller Capital Management L.P. Cuts Stock Holdings in BioLife Solutions, Inc. $BLFS

Rockefeller Capital Management L.P. lowered its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 30.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 705,863 shares of the medical equipment provider’s stock after selling 304,266 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in BioLife Solutions were worth $17,068,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of BLFS. The Manufacturers Life Insurance Company boosted its holdings in BioLife Solutions by 2.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock worth $447,000 after acquiring an additional 555 shares during the last quarter. Isthmus Partners LLC grew its stake in shares of BioLife Solutions by 0.5% in the 4th quarter. Isthmus Partners LLC now owns 138,393 shares of the medical equipment provider’s stock worth $3,346,000 after acquiring an additional 622 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of BioLife Solutions by 2.6% in the second quarter. Thrivent Financial for Lutherans now owns 27,278 shares of the medical equipment provider’s stock valued at $588,000 after purchasing an additional 702 shares during the last quarter. Quarry LP raised its holdings in shares of BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 713 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of BioLife Solutions by 2.9% during the third quarter. Millennium Management LLC now owns 27,698 shares of the medical equipment provider’s stock valued at $707,000 after purchasing an additional 783 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

Insider Transactions at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the completion of the sale, the insider owned 4,757,165 shares in the company, valued at approximately $112,744,810.50. This trade represents a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 1,200,000 shares of company stock worth $28,125,000 in the last three months. Company insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on BLFS shares. Zacks Research cut shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research report on Monday, April 20th. Finally, Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, BioLife Solutions has a consensus rating of “Hold” and a consensus target price of $32.00.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $24.88 on Wednesday. BioLife Solutions, Inc. has a 1 year low of $17.86 and a 1 year high of $29.62. The company has a market capitalization of $1.22 billion, a PE ratio of -310.96 and a beta of 2.00. The business has a fifty day moving average price of $23.63 and a two-hundred day moving average price of $22.94.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $27.50 million for the quarter, compared to analysts’ expectations of $25.66 million. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%. Sell-side analysts anticipate that BioLife Solutions, Inc. will post 0.07 earnings per share for the current year.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.